Skip to content

Vitamin D and depression

Evaluation of vitamin D supplementation effects on serum 25(OH)D3, PTH, pro-inflammatory biomarkers and neurotransmitters involved in depression, and depression status in depressive patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170926036425N1
Enrollment
60
Registered
2018-09-17
Start date
2018-04-04
Completion date
Unknown
Last updated
2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression. Major depressive disorder, single episode, unspecified

Interventions

Intervention 1: Intervention group: Every two weeks receives 50000 IU vitamin D as vitamin D supplementation for 8 weeks, which is provided on a monthly basis. Intervention 2: Control group:Every two

Sponsors

National Nutrition and Food Technology Researc Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: having mild to moderate depression age: 18 to 60 y

Exclusion criteria

Exclusion criteria: having a history of heart infarction having a history of angina having a history of stroke having a history of kidney stones having a history of high blood pressure (systolic blood pressure higher than 174 or diastolic blood pressure higher than 104 mm Hg) having a history of liver disease having a history of hyperparathyroidism pregnancy and/or lactation Reproductive-aged women (under 50 years old) who are not receiving adequate contraception consuming nutritional supplement containing vitamin D from 2 months ago

Design outcomes

Primary

MeasureTime frame
Serum 25(OH)D concentration. Timepoint: baseline and 8 weeks after intervention. Method of measurement: measurement of serum level of 25OHD.

Secondary

MeasureTime frame
Proinflammatory biomarkers. Timepoint: baseline and 8 weeks after intervention. Method of measurement: measurement of serum hs-CRP, IL-6, IL-1ß concentrations.;Bone biomarker. Timepoint: baseline and 8 weeks after intervention. Method of measurement: measurement of serum parathormone concentration.;Some neurotransmitters involved in depression. Timepoint: baseline and 8 weeks after intervention. Method of measurement: measurement of serum oxytocin and platelet serotonin concentrations.;Depression status. Timepoint: baseline and 8 weeks after intervention. Method of measurement: Using Beck questioner.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Kaviani

Islamic Azad University

mina_kaviani@yahoo.com+98 21 2236 0658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026